Patents by Inventor Thomas R. DIRAIMONDO

Thomas R. DIRAIMONDO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS RELATED TO TUMOR ACTIVATED ANTIBODIES TARGETING EGFR AND EFFECTOR CELL ANTIGENS
    Publication number: 20250177552
    Abstract: Provided herein are multispecific antibodies that selectively bind to EGFR and effector cell antigens such as CD3, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same.
    Type: Application
    Filed: October 17, 2024
    Publication date: June 5, 2025
    Inventors: David CAMPBELL, Thomas R. DIRAIMONDO, Ramesh BHATT
  • OPTIMIZED ANTIBODIES TARGETING TROP2 AND USES THEREOF
    Publication number: 20250154278
    Abstract: Disclosed herein are recombinant antibodies or antigen binding fragments thereof that comprise a tumor-associated calcium signal transducer 2 (TROP2) binding domain that has been optimized for binding and kinetic properties. In some embodiments, the recombinant antibodies or antigen binding fragments thereof further comprise a CD3 binding domain.
    Type: Application
    Filed: February 22, 2023
    Publication date: May 15, 2025
    Inventors: David CAMPBELL, Thomas R. DIRAIMONDO
  • CLEAVABLE LINKER COMPOSITIONS AND METHODS
    Publication number: 20250019403
    Abstract: Provided herein are cleavable linkers, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same. The cleavable linkers described herein have improved efficacy and safety.
    Type: Application
    Filed: September 19, 2024
    Publication date: January 16, 2025
    Inventors: David CAMPBELL, Thomas R. DiRaimondo
  • TRANSGLUTAMINASE 2 (TG2) INHIBITORS
    Publication number: 20250011324
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit transglutaminase 2 (TG2). Also described herein are methods for using such TG2 inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from TG2 inhibition.
    Type: Application
    Filed: September 6, 2024
    Publication date: January 9, 2025
    Inventors: David CAMPBELL, Justin CHAPMAN, Mui CHEUNG, Thomas R. DIRAIMONDO, Sergio G. DURON
  • Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigens
    Patent number: 12161724
    Abstract: Provided herein are multispecific antibodies for redirecting T cells to cancers, that rely on binding of one antigen interacting portion of the antibody to a tumor-associated antigen or marker, such as epidermal growth factor receptor (EGFR), while a second antigen interacting portion can bind to an effector cell antigen on a T cell, such as CD3, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same.
    Type: Grant
    Filed: May 4, 2022
    Date of Patent: December 10, 2024
    Assignee: JANUX THERAPEUTICS, INC.
    Inventors: David Campbell, Thomas R. Diraimondo, Ramesh Bhatt
  • Transglutaminase 2 (TG2) inhibitors
    Patent number: 12152026
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit transglutaminase 2 (TG2). Also described herein are methods for using such TG2 inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from TG2 inhibition.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: November 26, 2024
    Assignee: Sitari Pharma, Inc.
    Inventors: David Campbell, Justin Chapman, Mui Cheung, Thomas R. Diraimondo, Sergio G. Duron
  • COMPOSITIONS AND METHODS RELATING TO TUMOR ACTIVATED T CELL ENGAGERS
    Publication number: 20240376226
    Abstract: Provided herein are modified T cell engagers, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same. The modified T cell engagers described herein are modified with a peptide and a half-life extending molecule.
    Type: Application
    Filed: July 26, 2024
    Publication date: November 14, 2024
    Inventors: David CAMPBELL, Ramesh BHATT, Thomas R. DIRAIMONDO
  • COMPOSITIONS AND METHODS RELATED TO TUMOR ACTIVATED ANTIBODIES TARGETING EGFR AND EFFECTOR CELL ANTIGENS
    Publication number: 20240252669
    Abstract: Provided herein are multispecific antibodies for redirecting T cells to cancers, that rely on binding of one antigen interacting portion of the antibody to a tumor-associated antigen or marker, such as epidermal growth factor receptor (EGFR), while a second antigen interacting portion can bind to an effector cell antigen on a T cell, such as CD3, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same.
    Type: Application
    Filed: May 4, 2022
    Publication date: August 1, 2024
    Inventors: David CAMPBELL, Thomas R. DIRAIMONDO, Ramesh BHATT
  • ANTIBODIES TARGETING EGFR AND CD3 AND USES THEREOF
    Publication number: 20240254241
    Abstract: Provided herein are antibodies that selectively bind to EGFR and CD3, pharmaceutical compositions thereof, as well as methods of producing such antibodies.
    Type: Application
    Filed: May 10, 2022
    Publication date: August 1, 2024
    Inventors: David CAMPBELL, Thomas R. DIRAIMONDO, Ramesh BHATT
  • ANTIBODIES TARGETING TROP2 AND CD3 AND USES THEREOF
    Publication number: 20240092931
    Abstract: Provided herein are antibodies that selectively bind to TROP2 and CD3, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same.
    Type: Application
    Filed: August 23, 2021
    Publication date: March 21, 2024
    Inventors: David CAMPBELL, Thomas R. DIRAIMONDO
  • COMPOSITIONS AND METHODS RELATED TO TUMOR ACTIVATED ANTIBODIES TARGETING PSMA AND EFFECTOR CELL ANTIGENS
    Publication number: 20240059790
    Abstract: Described herein are compositions and formulations comprising a recombinant polypeptide. Related methods and uses of these compositions and formulations are also described herein.
    Type: Application
    Filed: May 8, 2023
    Publication date: February 22, 2024
    Inventors: David CAMPBELL, Thomas R. DIRAIMONDO, Carolina CAFFARO, Hans AERNI
  • ANTIBODIES TARGETING PSMA AND CD3 AND USES THEREOF
    Publication number: 20240043565
    Abstract: Provided herein are antibodies that selectively bind to PSMA and CD3, pharmaceutical compositions thereof, as well as methods of producing such antibodies.
    Type: Application
    Filed: October 14, 2021
    Publication date: February 8, 2024
    Inventors: David CAMPBELL, Thomas R. DIRAIMONDO
  • PEPTIDE COMPOSITIONS AND METHODS FOR ANTI-CD3 BINDING DOMAINS
    Publication number: 20240043536
    Abstract: Disclosed herein are polypeptide and polypeptide complex compositions that comprise a peptide that selectively impairs binding of an anti-CD3 binding domain to CD3 in healthy tissue but not in a disease state.
    Type: Application
    Filed: December 7, 2021
    Publication date: February 8, 2024
    Inventors: David CAMPBELL, Thomas R. DIRAIMONDO
  • HALF-LIFE EXTENDING COMPOSITIONS AND METHODS
    Publication number: 20240034814
    Abstract: Disclosed herein are polypeptides and polypeptides complexes comprising a half-life extending antibody or antibody fragment. In some embodiments, the half-life extending antibody or antibody fragment is a single domain antibody.
    Type: Application
    Filed: December 7, 2021
    Publication date: February 1, 2024
    Inventors: David CAMPBELL, Thomas R. DIRAIMONDO, Ramesh BHATT
  • COMPOSITIONS AND METHODS RELATED TO TUMOR ACTIVATED ANTIBODIES TARGETING TROP2 AND EFFECTOR CELL ANTIGENS
    Publication number: 20240034806
    Abstract: Provided herein are multispecific antibodies that selectively bind to TROP2 and effector cell antigens such as CD3, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same.
    Type: Application
    Filed: December 7, 2021
    Publication date: February 1, 2024
    Inventors: David CAMPBELL, Thomas R. DIRAIMONDO
  • MULTISPECIFIC ANTIBODIES FOR TARGETING CD28 AND PD-L1 AND METHODS OF USE THEREOF
    Publication number: 20230406937
    Abstract: Provided herein are antibodies that selectively bind to CD28 and PD-L1, pharmaceutical compositions thereof, as well as nucleic acids, and methods of use, and methods for making and discovering the same.
    Type: Application
    Filed: October 29, 2021
    Publication date: December 21, 2023
    Inventors: David CAMPBELL, Thomas R. DIRAIMONDO
  • ANTIBODIES TARGETING HER2 AND CD3 AND USES THEREOF
    Publication number: 20230406955
    Abstract: Provided herein are antibodies that selectively bind to HER2 and CD3, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same.
    Type: Application
    Filed: October 21, 2021
    Publication date: December 21, 2023
    Inventors: David CAMPBELL, Thomas R. DIRAIMONDO,
  • TUMOR ACTIVATED MULTISPECIFIC ANTIBODIES FOR TARGETING CD28 AND PD-L1 AND METHODS OF USE THEREOF
    Publication number: 20230357447
    Abstract: Provided herein are antibodies that selectively bind to CD28 and PD-L1, pharmaceutical compositions thereof, as well as nucleic acids, and methods of use, and methods for making and discovering the same.
    Type: Application
    Filed: May 8, 2023
    Publication date: November 9, 2023
    Inventors: David CAMPBELL, Thomas R. DIRAIMONDO
  • OPTIMIZED ANTIBODIES TARGETING TROP2 AND USES THEREOF
    Publication number: 20230357429
    Abstract: Disclosed herein are isolated polypeptides or polypeptide complexes that comprise a tumor-associated calcium signal transducer 2 (TROP2) binding domain that has been optimized for binding and kinetic properties. In some embodiments, the isolated polypeptides or polypeptide complexes further comprise a CD3 binding domain.
    Type: Application
    Filed: May 8, 2023
    Publication date: November 9, 2023
    Inventors: David CAMPBELL, Thomas R. DIRAIMONDO
  • COMPOSITIONS AND METHODS RELATED TO TUMOR ACTIVATED ANTIBODIES TARGETING PSMA AND EFFECTOR CELL ANTIGENS
    Publication number: 20230348618
    Abstract: Provided herein are multispecific antibodies that selectively bind to PSMA and effector cell antigens such as CD3, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same.
    Type: Application
    Filed: November 16, 2022
    Publication date: November 2, 2023
    Inventors: David CAMPBELL, Thomas R. DiRaimondo